Results 1 to 10 of about 3,679,309 (227)

Hypomethylating Agents in Oncohematology [PDF]

Клиническая онкогематология, 2016
The review describes epigenetic processes, including methylation of nuclear and mitochondrial DNA, as well as RNA. It dwells on mechanisms of demethylation and corresponding medicinal products.
Anton Dmitrievich Shirin, O. Yu. Baranova   +1 more
doaj   +2 more sources

Hypomethylating agents increase L1 retroelement expression without inducing novel insertions in myeloid malignancies [PDF]

Molecular Oncology
Retroelements in the human genome are silenced via multiple mechanisms, including DNA methylation, to prevent their potential mutagenic effect. Retroelement activity, demonstrated by their expression and somatic retrotransposition events, was shown to be
Šárka Pavlová, Hana Svozilová, Marcela Krzyžánková, Radim Sonnek, Anastasiya Volakhava, Anastasia Smirnova, Tatiana Grigoreva, Zuzana Jašková, Hana Synáčková, Dennis Wahl, Michaela Bilčíková, Libor Červinek, Šárka Pospíšilová, Ilgar Mamedov, Karla Plevová   +14 more
doaj   +2 more sources

Multi-Organ Adverse Reaction to Two Hypomethylating Agents: A Challenge in High-Risk Myelodysplastic Syndrome Treatment [PDF]

Hematology Reports
Background and Clinical Significance: Intermediate- to high-risk Myelodysplastic Syndrome (MDS), according to the Revised International Prognostic Scoring System (IPSS-M), confers a high risk of progression into acute myeloid leukemia.
Sofia Brites Alves, Francesca Pierdomenico   +1 more
doaj   +2 more sources

Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. [PDF]

Blood Cancer J
Hypomethylating agent (HMA) plus venetoclax (VEN) regimens are standard of care in patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy.
Willekens C, Bazinet A, Chraibi S, Bataller A, Decroocq J, Arani N, Carpentier B, Rausch C, Lebon D, Maiti A, Gauthier N, Short N, Bonnet S, Sasaki K, Khalife-Hachem S, Swaminathan M, Micol JB, Pasquier F, Marzac C, Roos-Weil D, Pascal L, Daver N, Kadia T, Bouscary D, Ravandi F, Pages A, Kantarjian H, De Botton S, DiNardo C.   +28 more
europepmc   +2 more sources

Antileukemic effect of venetoclax and hypomethylating agents via caspase-3/GSDME-mediated pyroptosis

Journal of Translational Medicine, 2023
Background The identifying of B-cell lymphoma 2 (Bcl-2) as a therapeutic target has led to a paradigm shift in acute myeloid leukemia (AML) treatment. Pyroptosis is a novel antitumor therapeutic mechanism due to its cytotoxic and immunogenic effects. The
Fanghua Ye, Wen Zhang, Chenying Fan, Jiajia Dong, Min Peng, Wenjun Deng, Hui Zhang, Liangchun Yang   +7 more
doaj   +2 more sources

TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS [PDF]

Mediterranean Journal of Hematology and Infectious Diseases, 2013
Patients with ≥ 20% 30% BM blast AML. In the present review, we will discuss the clinical results achieved in the treatment of elderly patients with 20%-30% BM blasts AML using intensive chemotherapy (IC) or hypomethylating agents.
Luca Maurillo, Francesco Buccisano, Maria Ilaria Del Principe, Chiara Sarlo, Luigi Di Caprio, Concetta Ditto, Federica Giannotti, Daniela Nasso, Eleonora Ceresoli, Massimiliano Postorino, Marco Refrigeri, Sergio Amadori, Adriano Venditti   +12 more
doaj   +4 more sources

TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS [PDF]

Mediterranean Journal of Hematology and Infectious Diseases, 2017
In 2002, the WHO classification reduced the proportion of blasts in the bone marrow (BM) necessary for the diagnosis of acute myeloid leukemia (AML) from 30% to 20%, eliminating the RAEB-t subtype of myelodysplastic syndromes (MDS).
Eleonora De Bellis, Luana Fianchi, Francesco Buccisano, Marianna Criscuolo, Luca Maurillo, Laura Cicconi, Mattia Brescini, Maria Ilaria Del Principe, Ambra Di Veroli, Adriano Venditti, Francesco Lo-Coco, Maria Teresa Voso   +11 more
doaj   +5 more sources

Differential Histone Posttranslational Modifications Induced by DNA Hypomethylating Agents [PDF]

Cancer Control, 2022
Introduction The prototype DNA hypomethylating agents 5-azacytidine (5AC) and decitabine (DAC) are currently FDA-approved for treatment of blood and bone marrow disorders like myelodysplastic syndrome.
Sridhar A Malkaram, Aymen Shatnawi, Jun Fan, Hetty Carraway, James Denvir, Donald A Primerano, Zakaria Y Abd Elmageed, Tamer E Fandy   +7 more
doaj   +3 more sources

Meta-analysis on hypomethylating agents in myelodysplastic syndromes

Haematologica, 2010
The addition of hypomethylating agents into the armatorium against myelodysplastic syndromes (MDS) is commonly accepted as a promising new therapeutic option in this otherwise frustrating field.
Christine Herbst, Kathrin Bauer, Karl-Anton Kreuzer   +2 more
doaj   +3 more sources

Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia

Case Reports in Hematology, 2021
Mixed phenotype acute leukemia (MPAL) is a rare hematological malignancy that lacks consensus on optimal management. We report for the first time two cases of treatment-naïve B/myeloid MPAL patients treated with a novel chemo-free regimen using ...
Di Wu, Wenlan Chen, Zhichao Chen, Qiubai Li   +3 more
doaj   +2 more sources